Saniona a clinical stage biopharmaceutical company focused on rare diseases announced that the U.S. Food and Drug Administration has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity. Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Saniona is preparing to initiate two Phase 2b studies of Tesomet in the second half of this year, one in HO and the other in Prader-Willi syndrome, for which Tesomet has already received orphan drug status.
- Read more about Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/saniona-receives-usfda-orphan-drug-designation-for-tesomet-in-hypothalamic-obesity
No comments:
Post a Comment